This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
2 Sep 2011

Roche’s Tarceva Receives European Approval

This approval will enable the use of Tarceva as a first-line monotherapy in people with locally advanced or metastatic NSCLC with EGFR (epidermal growth factor receptor) activating mutations.

The European Commission has approved Roche's Tarceva? (erlotinib) for use in patients with a genetically distinct type of non-small cell lung cancer (NSCLC) in Europe.

 

This approval will enable the use of Tarceva as a first-line monotherapy in people with locally advanced or metastatic NSCLC with EGFR (epidermal growth factor receptor) activating mutations.

 

Tumours with these mutations are responsive to Tarceva and treatment with this medicine has been shown to more than triple the number of patients whose tumours shrink (response rate). Tarceva has also shown to nearly double the time patients live without their disease progressing (progression free survival – PFS) compared to chemotherapy.

 

Related News